Assessing the translatability of drug projects: what needs to be scored to predict success?
Drug development projects have high attrition rates, often because efficacy and safety issues have not been foreseen. More effective prediction of 'translational success' could therefore have a key role in addressing the widely acknowledged problems with weak drug development pipelines. Here, I discuss how a scoring system to systematically assess key determinants of translational success, such as biomarkers and animal and human data, could help identify deficiencies and potential improvements, and increase the reliability of portfolio risk estimates.
Wehling
Martin
M
Department of Clinical Pharmacology Mannheim, University Medicine Mannheim, University of Heidelberg, Maybachstrasse 14, 68169 Mannheim, Germany. martin.wehling@medma.uni-heidelberg.de
D015415:Biomarkers; D055808:Drug Discovery; D004345:Drug Industry; D006801:Humans
D015415:Biomarkers